CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 4, 2016
Result type: Reports
Project Number: SR0495-000
Product Line: Reimbursement Review

Generic Name: Reslizumab

Brand Name: Cinqair

Manufacturer: TEVA Canada Innovation

Therapeutic Area: Asthma, eosinophilic

Indications: Asthma, eosinophilic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 22, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions